Source: Health Analytics
New guidance from the FDA urges drug development stakeholders to be transparent with their data as a way to maintain high quality and foster patient-centered precision medicine.
Innovative, personalized treatments are being developed at an accelerated pace, offering patients targeted therapies based on their genetic responses to treatment pathways.
However, in order for patients to fully leverage the benefits of these new, targeted therapies, drug companies must ensure that they communicate with patients and other healthcare stakeholders.
This article highlights the scope for developing therapeutics with new innovative, alternative approaches. The current trillion dollars pharmaceutical industry is in peril where the current drug development pipeline is slow, inefficient and incapable of being extended to multi-combination drug therapies as well as minimally focused on prevention. The complex modeling of diseases and biological functions has been limited because of the inability to integrate large scale molecular pathways.
Watch this Video to understand how recent advances provide breakthrough technology for doing scalable modeling of complex molecular systems to dramatically accelerate drug discovery and development.